{"id":1212,"date":"2022-03-01T14:00:30","date_gmt":"2022-03-01T14:00:30","guid":{"rendered":"https:\/\/astheworldturns.org\/wdp\/?p=1212"},"modified":"2024-06-15T23:07:47","modified_gmt":"2024-06-15T23:07:47","slug":"1011-case-studies-into-covid-vaccines","status":"publish","type":"post","link":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/","title":{"rendered":"1011 CASE STUDIES into the COVID VACCINES"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\n

<\/p>\n\n\n\n

  1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)01608-1\/<\/a><\/li>
  2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1052305721003414<\/a><\/li>
  3. Fatal cerebral hemorrhage after COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33928772\/<\/a><\/li>
  4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666602221000409<\/a><\/li>
  5. Three cases of acute venous thromboembolism in women after vaccination against COVID-19: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213333X21003929<\/a><\/li>
  6. Acute thrombosis of the coronary tree after vaccination against COVID-19: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1936879821003988<\/a><\/li>
  7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: https:\/\/pubmed.ncbi.nlm.nih.gov\/33929487\/<\/a><\/li>
  8. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(21)00197-7\/<\/a><\/li>
  9. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): https:\/\/pubmed.ncbi.nlm.nih.gov\/33871350\/<\/a><\/li>
  10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022510X21003014<\/a><\/li>
  11. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0735675721004381<\/a><\/li>
  12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0033062021000505<\/a><\/li>
  13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0953620521001904<\/a><\/li>
  14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1665268121000557<\/a><\/li>
  15. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1050173821000967<\/a><\/li>
  16. Roots of autoimmunity of thrombotic events after COVID-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1568997221002160<\/a><\/li>
  17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)01788-8\/fulltext<\/a><\/li>
  18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejme2106315<\/a><\/li>
  19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in \u201c23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine\u201d: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2781601<\/a><\/li>
  20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2104882?query=recirc_curatedRelated_article<\/a><\/li>
  21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: https:\/\/pubmed.ncbi.nlm.nih.gov\/34374740\/<\/a><\/li>
  22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2104840?query=recirc_curatedRelated_article<\/a><\/li>
  23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): https:\/\/haematologica.org\/article\/view\/haematol.2021.279075<\/a><\/li>
  24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X21005247<\/a><\/li>
  25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: https:\/\/pediatrics.aappublications.org\/content\/early\/2021\/06\/04\/peds.2021-052478<\/a><\/li>
  26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589238X21000292#f0005<\/a><\/li>
  27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0896841121000895<\/a><\/li>
  28. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0049384821003315<\/a><\/li>
  29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0896841121000937<\/a><\/li>
  30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1052305721003098<\/a><\/li>
  31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0953620521002363<\/a><\/li>
  32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0828282X21006243<\/a><\/li>
  33. \u201cPortal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome\u201d: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666572721000389<\/a><\/li>
  34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0196064421003425<\/a><\/li>
  35. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1443950621011562<\/a><\/li>
  36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0896841121000706<\/a><\/li>
  37. Prothrombotic immune thrombocytopenia after COVID-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497121009411<\/a><\/li>
  38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589936821000256<\/a><\/li>
  39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1871402121002046<\/a><\/li>
  40. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0049384821004369<\/a><\/li>
  41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109721051949<\/a><\/li>
  42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735675721005714<\/a><\/li>
  43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S088915912100163X<\/a><\/li>
  44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0006497121013963<\/a>.<\/li>
  45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel\u2019s back?: https:\/\/docs.google.com\/document\/d\/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ<\/a><\/li>
  46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0953620521002314<\/a><\/li>
  47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0213485321000839<\/a><\/li>
  48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the \u201cAstraZeneca COVID-19 vaccine\u201d: https:\/\/pubmed.ncbi.nlm.nih.gov\/33918932\/<\/a><\/li>
  49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33606296\/<\/a><\/li>
  50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33854395\/<\/a><\/li>
  51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7996471\/<\/a><\/li>
  52. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: https:\/\/pubmed.ncbi.nlm.nih.gov\/33863748\/<\/a><\/li>
  53. Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.26172<\/a><\/li>
  54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: https:\/\/pubmed.ncbi.nlm.nih.gov\/34133027\/<\/a><\/li>
  55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34001390\/<\/a><\/li>
  56. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: https:\/\/pubmed.ncbi.nlm.nih.gov\/34181446\/<\/a><\/li>
  57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https:\/\/pubmed.ncbi.nlm.nih.gov\/34174723\/<\/a><\/li>
  58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https:\/\/www.nature.com\/articles\/s41591-021-01408-4<\/a><\/li>
  59. Exacerbation of immune thrombocytopenia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34075578\/<\/a><\/li>
  60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34105244\/<\/a><\/li>
  61. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2106383<\/a><\/li>
  62. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: https:\/\/www.nature.com\/articles\/s41586-021-03744-4<\/a><\/li>
  63. Myocarditis with COVID-19 mRNA vaccines: https:\/\/www.ahajournals.org\/doi\/pdf\/10.1161\/CIRCULATIONAHA.121.056135<\/a><\/li>
  64. Myocarditis and pericarditis after COVID-19 vaccination: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2782900<\/a><\/li>
  65. Myocarditis temporally associated with COVID-19 vaccination: https:\/\/www.ahajournals.org\/doi\/pdf\/10.1161\/CIRCULATIONAHA.121.055891<\/a>.<\/li>
  66. COVID-19 Vaccination Associated with Myocarditis in Adolescents: https:\/\/pediatrics.aappublications.org\/content\/pediatrics\/early\/2021\/08\/12\/peds.2021-053427.full.pdf<\/a><\/li>
  67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/33994339\/<\/a><\/li>
  68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1553838921005789<\/a><\/li>
  69. COVID-19 vaccine-induced myocarditis: a case report with review of the literature: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1871402121002253<\/a><\/li>
  70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1936878X2100485X<\/a><\/li>
  71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S002234762100617X<\/a><\/li>
  72. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0167527321012286<\/a>.<\/li>
  73. Acute myocarditis after administration of BNT162b2 vaccine: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2214250921001530<\/a><\/li>
  74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352906721001573<\/a><\/li>
  75. Myocarditis following vaccination with BNT162b2 in a healthy male: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735675721005362<\/a><\/li>
  76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1930043321005549<\/a><\/li>
  77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S002234762100665X<\/a><\/li>
  78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1885585721002218<\/a><\/li>
  79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589790X21001931<\/a><\/li>
  80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352906721000622<\/a><\/li>
  81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022347621007368<\/a><\/li>
  82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0870255121003243<\/a><\/li>
  83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022347621007496<\/a><\/li>
  84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1936878X21004861<\/a><\/li>
  85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1443950621011331<\/a><\/li>
  86. COVID-19 mRNA vaccination and myocarditis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34268277\/<\/a><\/li>
  87. COVID-19 vaccine and myocarditis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34399967\/<\/a><\/li>
  88. Epidemiology and clinical features of myocarditis\/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study https:\/\/search.bvsalud.org\/global-literature-on-novel-coronavirus-2019-ncov\/resourc e\/en\/covidwho-1360706<\/a>.<\/li>
  89. COVID-19 vaccines and myocarditis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34246566\/<\/a><\/li>
  90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines https:\/\/www.cureus.com\/articles\/61030-myocarditis-and-other-cardiovascular-comp<\/a> lications-of-the-mrna-based-covid-19-vaccines https:\/\/www.cureus.com\/articles\/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines<\/a><\/li>
  91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34340927\/<\/a><\/li>
  92. Myocarditis with covid-19 mRNA vaccines: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.121.056135<\/a><\/li>
  93. Association of myocarditis with COVID-19 mRNA vaccine in children: https:\/\/media.jamanetwork.com\/news-item\/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children\/<\/a><\/li>
  94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2783052<\/a><\/li>
  95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2781601%5C<\/a><\/li>
  96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2781600<\/a><\/li>
  97. Myocarditis following immunization with Covid-19 mRNA: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2109975<\/a><\/li>
  98. Patients with acute myocarditis after vaccination withCOVID-19 mRNA: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2781602<\/a><\/li>
  99. Myocarditis associated with vaccination with COVID-19 mRNA: https:\/\/pubs.rsna.org\/doi\/10.1148\/radiol.2021211430<\/a><\/li>
  100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: https:\/\/pediatrics.aappublications.org\/content\/148\/3\/e2021052478<\/a><\/li>
  101. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https:\/\/jcmr-online.biomedcentral.com\/articles\/10.1186\/s12968-021-00795-4<\/a><\/li>
  102. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: https:\/\/www.cps.ca\/en\/documents\/position\/clinical-guidance-for-youth-with-myocarditis-and-pericarditis<\/a><\/li>
  103. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34402228\/<\/a><\/li>
  104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: https:\/\/academic.oup.com\/ehjcr\/article\/5\/8\/ytab319\/6339567<\/a><\/li>
  105. Myocarditis \/ pericarditis associated with COVID-19 vaccine: https:\/\/science.gc.ca\/eic\/site\/063.nsf\/eng\/h_98291.html<\/a><\/li>
  106. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https:\/\/journals.lww.com\/pidj\/Abstract\/9000\/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx<\/a><\/li>
  107. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https:\/\/academic.oup.com\/jpids\/advance-article\/doi\/10.1093\/jpids\/piab060\/6329543<\/a><\/li>
  108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: https:\/\/pubmed.ncbi.nlm.nih.gov\/34312010\/<\/a><\/li>
  109. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: https:\/\/pubmed.ncbi.nlm.nih.gov\/34219532\/<\/a><\/li>
  110. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: https:\/\/www.xiahepublishing.com\/m\/2472-0712\/ERHM-2021-00033<\/a><\/li>
  111. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCIMAGING.121.013236<\/a><\/li>
  112. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.121.056038<\/a><\/li>
  113. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: https:\/\/pubmed.ncbi.nlm.nih.gov\/34333695\/<\/a><\/li>
  114. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8216855\/<\/a><\/li>
  115. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: https:\/\/pubmed.ncbi.nlm.nih.gov\/34118375\/<\/a><\/li>
  116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34180390\/<\/a><\/li>
  117. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34133825\/<\/a><\/li>
  118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34487236\/<\/a><\/li>
  119. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciab741\/6359059<\/a><\/li>
  120. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34447639\/<\/a><\/li>
  121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02183<\/a><\/li>
  122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https:\/\/pubmed.ncbi.nlm.nih.gov\/34236331\/<\/a><\/li>
  123. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34435250\/<\/a><\/li>
  124. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: https:\/\/pubmed.ncbi.nlm.nih.gov\/34186348\/<\/a>.<\/li>
  125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666354621000065<\/a><\/li>
  126. Guillain-Barr\u00e9 syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0303846721004169<\/a><\/li>
  127. Sensory Guillain-Barr\u00e9 syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165572821002186<\/a><\/li>
  128. Guillain-Barr\u00e9 syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2214250921000998<\/a>.<\/li>
  129. Guillain-Barr\u00e9 syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0736467921006442<\/a><\/li>
  130. Guillain-Barr\u00e9 syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0035378721005853<\/a>.<\/li>
  131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2049080121005343<\/a><\/li>
  132. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2049080121007536<\/a><\/li>
  133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1201971221007049<\/a><\/li>
  134. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0899707121003557<\/a>.<\/li>
  135. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165572821001569<\/a><\/li>
  136. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165572821002137<\/a><\/li>
  137. Bell\u2019s palsy and SARS-CoV-2 vaccines: an unfolding story: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1473309921002735<\/a><\/li>
  138. Bell\u2019s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell\u2019s palsy: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S266635462100020X<\/a><\/li>
  139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2451993621001456<\/a>.<\/li>
  140. Bell\u2019s palsy after COVID-19 vaccination: case report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S217358082100122X<\/a>.<\/li>
  141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient\u2019s allergy history: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213219821007972<\/a><\/li>
  142. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1930043321002612<\/a><\/li>
  143. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0272638621007423<\/a><\/li>
  144. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213219821007996<\/a><\/li>
  145. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1871402121001880<\/a><\/li>
  146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0190962221024427<\/a><\/li>
  147. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0735675721004381<\/a>.<\/li>
  148. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1939455121000119<\/a>.<\/li>
  149. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1871402121002046<\/a>.<\/li>
  150. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S188558572100133X<\/a><\/li>
  151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0896841121000937<\/a>.<\/li>
  152. immune thrombocytopenia associated with Pfizer-BioNTech\u2019s COVID-19 BNT162b2 mRNA vaccine:. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2214250921002018<\/a>.<\/li>
  153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1876034121001878<\/a>.<\/li>
  154. COVID-19 RNA-based vaccines and the risk of prion disease: https:\/\/scivisionpub.com\/pdfs\/covid19rna-based-vaccines-and-the-risk-of-prion-dis<\/a> ease-1503.pdf<\/li>
  155. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2104983<\/a>.<\/li>
  156. Process-related impurities in the ChAdOx1 nCov-19 vaccine: https:\/\/www.researchsquare.com\/article\/rs-477964\/v1<\/a><\/li>
  157. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10780-7<\/a><\/li>
  158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33475702\/<\/a><\/li>
  159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: https:\/\/pubmed.ncbi.nlm.nih.gov\/33320974\/<\/a><\/li>
  160. Pfizer Vaccine Raises Allergy Concerns: https:\/\/pubmed.ncbi.nlm.nih.gov\/33384356\/<\/a><\/li>
  161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine \u2013 United States, December 14-23, 2020: https:\/\/pubmed.ncbi.nlm.nih.gov\/33444297\/<\/a><\/li>
  162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine \u2013 United States, December 21, 2020-January 10, 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/33507892\/<\/a><\/li>
  163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/34414880\/<\/a><\/li>
  164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/33576785\/<\/a><\/li>
  165. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: https:\/\/pubmed.ncbi.nlm.nih.gov\/34269740\/<\/a><\/li>
  166. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34215453\/<\/a><\/li>
  167. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: https:\/\/pubmed.ncbi.nlm.nih.gov\/33932618\/<\/a><\/li>
  168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer \/ BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https:\/\/pubmed.ncbi.nlm.nih.gov\/33643776\/<\/a><\/li>
  169. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/33571463\/<\/a><\/li>
  170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: https:\/\/pubmed.ncbi.nlm.nih.gov\/33527524\/<\/a><\/li>
  171. Cutaneous adverse effects of available COVID-19 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34518015\/<\/a><\/li>
  172. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34347278\/<\/a><\/li>
  173. COVID-19 vaccines increase the risk of anaphylaxis: https:\/\/pubmed.ncbi.nlm.nih.gov\/33685103\/<\/a><\/li>
  174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34050949\/<\/a><\/li>
  175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: https:\/\/pubmed.ncbi.nlm.nih.gov\/33657648\/<\/a><\/li>
  176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer \/ BioNTech mRNA COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33825239\/<\/a><\/li>
  177. Acute allergic reactions to COVID-19 mRNA vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/33683290\/<\/a><\/li>
  178. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: https:\/\/pubmed.ncbi.nlm.nih.gov\/33919151\/<\/a><\/li>
  179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https:\/\/pubmed.ncbi.nlm.nih.gov\/34128049\/<\/a><\/li>
  180. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: https:\/\/pubmed.ncbi.nlm.nih.gov\/34474708\/<\/a><\/li>
  181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/17843286.2021.1909447<\/a><\/li>
  182. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34318537\/<\/a><\/li>
  183. Allergic reactions after COVID-19 vaccination: putting the risk in perspective: https:\/\/pubmed.ncbi.nlm.nih.gov\/34463751\/<\/a><\/li>
  184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https:\/\/pubmed.ncbi.nlm.nih.gov\/33846043\/<\/a> 188.<\/li>
  185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: https:\/\/pubmed.ncbi.nlm.nih.gov\/33752263\/<\/a><\/li>
  186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34073536\/<\/a><\/li>
  187. Fatal brain hemorrhage after COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33928772\/<\/a><\/li>
  188. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: https:\/\/pubmed.ncbi.nlm.nih.gov\/34423106\/<\/a><\/li>
  189. Skin reactions reported after Moderna and Pfizer\u2019s COVID-19 vaccination: a study based on a registry of 414 cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/33838206\/<\/a><\/li>
  190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34517079\/<\/a><\/li>
  191. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34254291\/<\/a><\/li>
  192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: https:\/\/pubmed.ncbi.nlm.nih.gov\/34487581\/<\/a><\/li>
  193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/33987882\/<\/a><\/li>
  194. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34138513\/<\/a><\/li>
  195. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https:\/\/pubmed.ncbi.nlm.nih.gov\/34402235\/<\/a><\/li>
  196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34446426\/<\/a><\/li>
  197. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https:\/\/pubmed.ncbi.nlm.nih.gov\/34365148\/<\/a>.<\/li>
  198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https:\/\/pubmed.ncbi.nlm.nih.gov\/34452064\/<\/a>.<\/li>
  199. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33917902\/<\/a><\/li>
  200. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https:\/\/pubmed.ncbi.nlm.nih.gov\/34256983\/<\/a><\/li>
  201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34247246\/<\/a>.<\/li>
  202. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34132839\/<\/a><\/li>
  203. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34117206\/<\/a><\/li>
  204. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https:\/\/pubmed.ncbi.nlm.nih.gov\/34033927\/<\/a><\/li>
  205. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34277198\/<\/a><\/li>
  206. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34364831\/<\/a><\/li>
  207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: https:\/\/pubmed.ncbi.nlm.nih.gov\/34447639\/<\/a><\/li>
  208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: https:\/\/pubmed.ncbi.nlm.nih.gov\/34514306\/<\/a><\/li>
  209. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA\/DNA vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/33946748\/<\/a><\/li>
  210. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34453510\/<\/a><\/li>
  211. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33476455\/<\/a><\/li>
  212. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34451967\/<\/a><\/li>
  213. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34377889\/<\/a><\/li>
  214. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34272095\/<\/a><\/li>
  215. COVID-19 vaccination association and facial nerve palsy: A case-control study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34165512\/<\/a><\/li>
  216. The association between COVID-19 vaccination and Bell\u2019s palsy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34411533\/<\/a><\/li>
  217. Bell\u2019s palsy after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33611630\/<\/a><\/li>
  218. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): https:\/\/pubmed.ncbi.nlm.nih.gov\/33981305\/<\/a><\/li>
  219. Bell\u2019s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34336436\/<\/a><\/li>
  220. Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34281950\/<\/a>.<\/li>
  221. Transverse myelitis induced by SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34458035\/<\/a><\/li>
  222. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): https:\/\/pubmed.ncbi.nlm.nih.gov\/33734623\/<\/a><\/li>
  223. Acute abducens nerve palsy after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34044114\/<\/a>.<\/li>
  224. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: https:\/\/pubmed.ncbi.nlm.nih.gov\/34492394\/<\/a><\/li>
  225. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34369471\/<\/a><\/li>
  226. Bell\u2019s palsy after Ad26.COV2.S COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34014316\/<\/a><\/li>
  227. Bell\u2019s palsy after COVID-19 vaccination: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34330676\/<\/a><\/li>
  228. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34272622\/<\/a><\/li>
  229. Guillian Barr\u00e9 syndrome after vaccination with mRNA-1273 against COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34477091\/<\/a><\/li>
  230. Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33975372\/<\/a>.<\/li>
  231. Bell\u2019s palsy after COVID-19 vaccination with high antibody response in CSF: https:\/\/pubmed.ncbi.nlm.nih.gov\/34322761\/<\/a>.<\/li>
  232. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: \u201cNeuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy\u201d by Coll et al. Articular Spine 2021; 88: 10519: https:\/\/pubmed.ncbi.nlm.nih.gov\/34139321\/<\/a>.<\/li>
  233. Bell\u2019s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34032902\/<\/a>.<\/li>
  234. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: https:\/\/pubmed.ncbi.nlm.nih.gov\/33862041\/<\/a><\/li>
  235. Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34332438\/<\/a><\/li>
  236. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: https:\/\/pubmed.ncbi.nlm.nih.gov\/34293683\/<\/a>.<\/li>
  237. Autoimmune hepatitis after COVID vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34225251\/<\/a><\/li>
  238. A novel case of bifacial diplegia variant of Guillain-Barr\u00e9 syndrome after vaccination with Janssen COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34449715\/<\/a><\/li>
  239. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34139631\/<\/a>.<\/li>
  240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/33864750\/<\/a><\/li>
  241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/33914590\/<\/a><\/li>
  242. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34420802\/<\/a><\/li>
  243. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https:\/\/pubmed.ncbi.nlm.nih.gov\/34293217\/<\/a><\/li>
  244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34446426\/<\/a><\/li>
  245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https:\/\/pubmed.ncbi.nlm.nih.gov\/34174723\/<\/a><\/li>
  246. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https:\/\/pubmed.ncbi.nlm.nih.gov\/33952445\/<\/a><\/li>
  247. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: https:\/\/pubmed.ncbi.nlm.nih.gov\/34108714\/<\/a><\/li>
  248. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https:\/\/pubmed.ncbi.nlm.nih.gov\/34288044\/<\/a><\/li>
  249. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34341358\/<\/a><\/li>
  250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261633\/<\/a>.<\/li>
  251. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34256983\/<\/a><\/li>
  252. Thrombocytopenia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34332437\/<\/a>.<\/li>
  253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33845870\/<\/a>.<\/li>
  254. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: https:\/\/pubmed.ncbi.nlm.nih.gov\/34236343\/<\/a><\/li>
  255. Acute myocardial infarction within 24 hours after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34364657\/<\/a>.<\/li>
  256. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34287612\/<\/a><\/li>
  257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https:\/\/pubmed.ncbi.nlm.nih.gov\/34478433\/<\/a><\/li>
  258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https:\/\/pubmed.ncbi.nlm.nih.gov\/34402235\/<\/a><\/li>
  259. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https:\/\/pubmed.ncbi.nlm.nih.gov\/34186376\/<\/a><\/li>
  260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34101024\/<\/a><\/li>
  261. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34137813\/<\/a><\/li>
  262. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34191218\/<\/a><\/li>
  263. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34175640\/<\/a><\/li>
  264. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34153802\/<\/a><\/li>
  265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34092488\/<\/a><\/li>
  266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261635\/<\/a><\/li>
  267. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34132839\/<\/a>.<\/li>
  268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34144250\/<\/a><\/li>
  269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33687691\/<\/a><\/li>
  270. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34011137\/<\/a>.<\/li>
  271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34393988\/<\/a>.<\/li>
  272. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34129181\/<\/a>.<\/li>
  273. Atypical thrombosis associated with the vaccine VaxZevria\u00ae (AstraZeneca): data from the French network of regional pharmacovigilance centers: https:\/\/pubmed.ncbi.nlm.nih.gov\/34083026\/<\/a>.<\/li>
  274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34247246\/<\/a>.<\/li>
  275. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: https:\/\/pubmed.ncbi.nlm.nih.gov\/34235757\/<\/a>.<\/li>
  276. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34473841\/<\/a>.<\/li>
  277. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34189756\/<\/a><\/li>
  278. Cerebral venous thrombosis following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34045111\/<\/a>.<\/li>
  279. Lipsch\u00fctz ulcers after AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34366434\/<\/a>.<\/li>
  280. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34330677\/<\/a><\/li>
  281. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: https:\/\/pubmed.ncbi.nlm.nih.gov\/34181446\/<\/a><\/li>
  282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34477089\/<\/a><\/li>
  283. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https:\/\/pubmed.ncbi.nlm.nih.gov\/34071883\/<\/a><\/li>
  284. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https:\/\/pubmed.ncbi.nlm.nih.gov\/34033367\/<\/a><\/li>
  285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https:\/\/pubmed.ncbi.nlm.nih.gov\/34375510\/<\/a><\/li>
  286. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34107198\/<\/a><\/li>
  287. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34355379\/<\/a>.<\/li>
  288. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34452028\/<\/a><\/li>
  289. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https:\/\/pubmed.ncbi.nlm.nih.gov\/34202817\/<\/a><\/li>
  290. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34237213\/<\/a>.<\/li>
  291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34105247\/<\/a>.<\/li>
  292. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34405870\/<\/a>.<\/li>
  293. Sensory Guillain-Barr\u00e9 syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34416410\/<\/a>.<\/li>
  294. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34462013\/<\/a>.<\/li>
  295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34224024\/<\/a>.<\/li>
  296. Post-vaccinal encephalitis after ChAdOx1 nCov-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34324214\/<\/a><\/li>
  297. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https:\/\/pubmed.ncbi.nlm.nih.gov\/34507266\/<\/a><\/li>
  298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: https:\/\/pubmed.ncbi.nlm.nih.gov\/34459725\/<\/a><\/li>
  299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34463066\/<\/a><\/li>
  300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/34043800\/<\/a>.<\/li>
  301. Facial diplegia: a rare and atypical variant of Guillain-Barr\u00e9 syndrome and the Ad26.COV2.S vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34447646\/<\/a><\/li>
  302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34479760\/<\/a>.<\/li>
  303. fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https:\/\/pubmed.ncbi.nlm.nih.gov\/34416319\/<\/a>.<\/li>
  304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): https:\/\/pubmed.ncbi.nlm.nih.gov\/34092166\/<\/a><\/li>
  305. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34291477\/<\/a><\/li>
  306. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34513435\/<\/a><\/li>
  307. Hepatitis C virus reactivation after COVID-19 vaccination: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34512037\/<\/a><\/li>
  308. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34483273\/<\/a>.<\/li>
  309. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: https:\/\/pubmed.ncbi.nlm.nih.gov\/34513446\/<\/a><\/li>
  310. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO \u00d7 1 nCov-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34474550\/<\/a><\/li>
  311. Reactive arthritis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34033732\/<\/a>.<\/li>
  312. Two cases of Graves\u2019 disease after SARS-CoV-2 vaccination: an autoimmune \/ inflammatory syndrome induced by adjuvants: https:\/\/pubmed.ncbi.nlm.nih.gov\/33858208\/<\/a><\/li>
  313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https:\/\/pubmed.ncbi.nlm.nih.gov\/34015240\/<\/a><\/li>
  314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34482558\/<\/a><\/li>
  315. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34480607\/<\/a><\/li>
  316. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34462647\/<\/a><\/li>
  317. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34325334\/<\/a><\/li>
  318. Tolosa-Hunt syndrome occurring after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34513398\/<\/a><\/li>
  319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https:\/\/pubmed.ncbi.nlm.nih.gov\/34362727\/<\/a><\/li>
  320. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): https:\/\/pubmed.ncbi.nlm.nih.gov\/34469919\/<\/a>.<\/li>
  321. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34516272\/<\/a>.<\/li>
  322. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34512961\/<\/a><\/li>
  323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34077949\/<\/a><\/li>
  324. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): https:\/\/pubmed.ncbi.nlm.nih.gov\/34171435\/<\/a><\/li>
  325. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34447349\/<\/a><\/li>
  326. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: https:\/\/pubmed.ncbi.nlm.nih.gov\/34514078\/<\/a><\/li>
  327. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34406660\/<\/a>.<\/li>
  328. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34509658\/<\/a><\/li>
  329. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34196469\/<\/a>.<\/li>
  330. Onset \/ outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca \/ Covishield): report of two cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34350668\/<\/a><\/li>
  331. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34436620\/<\/a><\/li>
  332. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https:\/\/pubmed.ncbi.nlm.nih.gov\/34116295\/<\/a>.<\/li>
  333. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: https:\/\/pubmed.ncbi.nlm.nih.gov\/34509271\/<\/a>.<\/li>
  334. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34462996\/<\/a><\/li>
  335. Immune thrombocytopenia after vaccination during the COVID-19 pandemic: https:\/\/pubmed.ncbi.nlm.nih.gov\/34435486\/<\/a><\/li>
  336. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed\/developing countries: https:\/\/pubmed.ncbi.nlm.nih.gov\/34435142\/<\/a><\/li>
  337. Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34429981\/<\/a><\/li>
  338. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34427024\/<\/a><\/li>
  339. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34510014\/<\/a>.<\/li>
  340. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34236711\/<\/a><\/li>
  341. Vaccine-induced thrombocytopenia with severe headache: https:\/\/pubmed.ncbi.nlm.nih.gov\/34525282\/<\/a><\/li>
  342. Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34515024\/<\/a><\/li>
  343. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34435250\/<\/a>.<\/li>
  344. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34363637\/<\/a><\/li>
  345. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2214250921002018<\/a><\/li>
  346. Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: https:\/\/casereports.bmj.com\/content\/14\/5\/e242220.abstract<\/a>.<\/li>
  347. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34155844\/<\/a><\/li>
  348. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8176657\/<\/a>.<\/li>
  349. Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: https:\/\/www.annemergmed.com\/article\/S0196-0644(21)00122-0\/fulltext<\/a>.<\/li>
  350. Thrombocytopenia after Pfizer and Moderna SARS vaccination \u2013 CoV -2: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8014568\/<\/a>.<\/li>
  351. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: https:\/\/casereports.bmj.com\/content\/14\/7\/e242678<\/a>.<\/li>
  352. Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: https:\/\/ashpublications.org\/bloodadvances\/article\/5\/13\/2794\/476324\/Autoimmune-and-complement-mediated-hematologic<\/a><\/li>
  353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: https:\/\/ejhp.bmj.com\/content\/early\/2021\/05\/23\/ejhpharm-2021-002794<\/a><\/li>
  354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: https:\/\/ashpublications.org\/blood\/article\/137\/26\/3670\/475905\/COVID-19-vaccines-induce-severe-hemolysis-in<\/a><\/li>
  355. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https:\/\/pubmed.ncbi.nlm.nih.gov\/34288044\/<\/a>.<\/li>
  356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: https:\/\/pubmed.ncbi.nlm.nih.gov\/34327553\/<\/a>.<\/li>
  357. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33878469\/<\/a>.<\/li>
  358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https:\/\/pubmed.ncbi.nlm.nih.gov\/33857630\/<\/a>.<\/li>
  359. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34090750\/<\/a>.<\/li>
  360. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34312301\/<\/a>.<\/li>
  361. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34333995\/<\/a><\/li>
  362. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34455073\/<\/a><\/li>
  363. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34111775\/<\/a>.<\/li>
  364. Cerebral venous thrombosis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34045111\/<\/a><\/li>
  365. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33983464\/<\/a><\/li>
  366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34116145\/<\/a><\/li>
  367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34286453\/<\/a>.<\/li>
  368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https:\/\/pubmed.ncbi.nlm.nih.gov\/34478433\/<\/a><\/li>
  369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: https:\/\/pubmed.ncbi.nlm.nih.gov\/34244448\/<\/a><\/li>
  370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https:\/\/pubmed.ncbi.nlm.nih.gov\/34226070\/<\/a><\/li>
  371. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/33845870\/<\/a>.<\/li>
  372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34101024\/<\/a>.<\/li>
  373. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34393988\/<\/a>.<\/li>
  374. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/34407607\/<\/a>.<\/li>
  375. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34313952\/<\/a><\/li>
  376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https:\/\/pubmed.ncbi.nlm.nih.gov\/34092166\/<\/a><\/li>
  377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https:\/\/pubmed.ncbi.nlm.nih.gov\/34293217\/<\/a><\/li>
  378. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34274191\/<\/a><\/li>
  379. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https:\/\/pubmed.ncbi.nlm.nih.gov\/34186376\/<\/a><\/li>
  380. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https:\/\/pubmed.ncbi.nlm.nih.gov\/33952445\/<\/a><\/li>
  381. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34129181\/<\/a><\/li>
  382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/33929487\/<\/a>.<\/li>
  383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34341358\/<\/a><\/li>
  384. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34175640\/<\/a><\/li>
  385. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https:\/\/pubmed.ncbi.nlm.nih.gov\/34159588\/<\/a>.<\/li>
  386. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https:\/\/pubmed.ncbi.nlm.nih.gov\/34402666\/<\/a><\/li>
  387. Autoimmunity roots of thrombotic events after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34508917\/<\/a><\/li>
  388. Cerebral venous sinus thrombosis after vaccination: the UK experience: https:\/\/pubmed.ncbi.nlm.nih.gov\/34370974\/<\/a><\/li>
  389. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34373991\/<\/a><\/li>
  390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34490632\/<\/a><\/li>
  391. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 \/ polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33909350\/<\/a><\/li>
  392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33981305\/<\/a>.<\/li>
  393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. https:\/\/pubmed.ncbi.nlm.nih.gov\/34272622\/<\/a><\/li>
  394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. https:\/\/pubmed.ncbi.nlm.nih.gov\/33877737\/<\/a><\/li>
  395. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34254476\/<\/a><\/li>
  396. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https:\/\/pubmed.ncbi.nlm.nih.gov\/34108714\/<\/a><\/li>
  397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: https:\/\/pubmed.ncbi.nlm.nih.gov\/34483267\/<\/a>.<\/li>
  398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261635\/<\/a><\/li>
  399. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https:\/\/pubmed.ncbi.nlm.nih.gov\/34202817\/<\/a><\/li>
  400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34273119\/<\/a><\/li>
  401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34463066\/<\/a><\/li>
  402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34276917\/<\/a><\/li>
  403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34237213\/<\/a>.<\/li>
  404. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): https:\/\/pubmed.ncbi.nlm.nih.gov\/34268278\/<\/a>.<\/li>
  405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/33990339\/<\/a>.<\/li>
  406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34479760\/<\/a>.<\/li>
  407. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: https:\/\/pubmed.ncbi.nlm.nih.gov\/34314875\/<\/a>.<\/li>
  408. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34384129\/<\/a><\/li>
  409. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: https:\/\/pubmed.ncbi.nlm.nih.gov\/34382387\/<\/a><\/li>
  410. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https:\/\/pubmed.ncbi.nlm.nih.gov\/34416184\/<\/a>.<\/li>
  411. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261297\/<\/a><\/li>
  412. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261296\/<\/a><\/li>
  413. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34250318\/<\/a>.<\/li>
  414. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34059191\/<\/a><\/li>
  415. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34189756\/<\/a><\/li>
  416. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34331506\/<\/a><\/li>
  417. Vaccine-induced thrombocytopenia with severe headache: https:\/\/pubmed.ncbi.nlm.nih.gov\/34525282\/<\/a><\/li>
  418. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.08.30.21262866v1<\/a><\/li>
  419. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.09.13.21262182v1.full?s=09<\/a>.<\/li>
  420. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16672<\/a><\/li>
  421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https:\/\/t.co\/j0IEM8cMXI<\/a><\/li>
  422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: https:\/\/pubmed.ncbi.nlm.nih.gov\/34601006\/<\/a><\/li>
  423. This study concludes that: \u201cThe vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection\u201d: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2110475<\/a><\/li>
  424. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1201971221007797<\/a><\/li>
  425. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.08.30.21262866v1<\/a>.<\/li>
  426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827821020936<\/a><\/li>
  427. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: https:\/\/www.nature.com\/articles\/s41421-021-00329-3<\/a><\/li>
  428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: https:\/\/www.ncbi.nlm.nih.gov\/labs\/pmc\/articles\/PMC8553377\/<\/a><\/li>
  429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: https:\/\/www.ahajournals.org\/doi\/10.1161\/circ.144.suppl_1.10712<\/a><\/li>
  430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:https:\/\/www.science.org\/doi\/10.1126\/sciadv.abl8213<\/a><\/li>
  431. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: https:\/\/pubmed.ncbi.nlm.nih.gov\/34626338\/<\/a><\/li>
  432. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: https:\/\/europepmc.org\/article\/PPR\/PPR304469 435<\/a>.<\/li>
  433. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34731555\/<\/a><\/li>
  434. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https:\/\/pubmed.ncbi.nlm.nih.gov\/34159588\/<\/a><\/li>
  435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34461442\/<\/a><\/li>
  436. Spectrum of neurological complications after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34719776\/<\/a>.<\/li>
  437. Cerebral venous sinus thrombosis after vaccination: the UK experience: https:\/\/pubmed.ncbi.nlm.nih.gov\/34370974\/<\/a><\/li>
  438. Cerebral venous vein\/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34373413\/<\/a><\/li>
  439. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34598301\/<\/a><\/li>
  440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34620638\/<\/a><\/li>
  441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https:\/\/pubmed.ncbi.nlm.nih.gov\/34650896\/<\/a><\/li>
  442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34625447\/<\/a><\/li>
  443. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: https:\/\/pubmed.ncbi.nlm.nih.gov\/34696248\/<\/a><\/li>
  444. Guillain-Barr\u00e9 syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34548920\/<\/a><\/li>
  445. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): https:\/\/pubmed.ncbi.nlm.nih.gov\/34672380\/<\/a>.<\/li>
  446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34556531\/<\/a>.<\/li>
  447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34535076\/<\/a>.<\/li>
  448. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34379914\/<\/a>.<\/li>
  449. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: https:\/\/pubmed.ncbi.nlm.nih.gov\/34545400\/<\/a><\/li>
  450. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34035134\/<\/a><\/li>
  451. In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34688190\/<\/a><\/li>
  452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34782400\/<\/a><\/li>
  453. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: https:\/\/pubmed.ncbi.nlm.nih.gov\/34710832\/<\/a><\/li>
  454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: https:\/\/pubmed.ncbi.nlm.nih.gov\/34695859\/<\/a><\/li>
  455. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34453762\/<\/a>.<\/li>
  456. Possible triggers of thrombocytopenia and\/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: https:\/\/pubmed.ncbi.nlm.nih.gov\/34660652\/<\/a>.<\/li>
  457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34644642\/<\/a><\/li>
  458. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https:\/\/pubmed.ncbi.nlm.nih.gov\/34694650\/<\/a><\/li>
  459. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34726934\/<\/a><\/li>
  460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34835237\/<\/a><\/li>
  461. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261297\/<\/a><\/li>
  462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34724036\/<\/a>.<\/li>
  463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34839563\/<\/a><\/li>
  464. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34783932\/<\/a>.<\/li>
  465. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: https:\/\/pubmed.ncbi.nlm.nih.gov\/34624910\/<\/a><\/li>
  466. Inflammatory myositis after vaccination with ChAdOx1: https:\/\/pubmed.ncbi.nlm.nih.gov\/34585145\/<\/a><\/li>
  467. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): https:\/\/pubmed.ncbi.nlm.nih.gov\/34580132\/<\/a>.<\/li>
  468. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: https:\/\/pubmed.ncbi.nlm.nih.gov\/34535492\/<\/a><\/li>
  469. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34527501\/<\/a><\/li>
  470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34272095\/<\/a><\/li>
  471. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34756770\/<\/a><\/li>
  472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2784622<\/a><\/li>
  473. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34781321\/<\/a><\/li>
  474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34062319\/<\/a><\/li>
  475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: https:\/\/pubmed.ncbi.nlm.nih.gov\/34706921\/<\/a><\/li>
  476. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34698582\/<\/a>.<\/li>
  477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34751013\/<\/a>.<\/li>
  478. Acute transverse myelitis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34684047\/<\/a>.<\/li>
  479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34541935\/<\/a><\/li>
  480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34273119\/<\/a><\/li>
  481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: https:\/\/pubmed.ncbi.nlm.nih.gov\/34327553\/<\/a>.<\/li>
  482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33877737\/<\/a><\/li>
  483. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34646685\/<\/a><\/li>
  484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34242687\/<\/a>.<\/li>
  485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34609603\/<\/a><\/li>
  486. Case report: Pityriasis rosea-like rash after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34557507\/<\/a><\/li>
  487. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34641797\/<\/a>.<\/li>
  488. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: https:\/\/pubmed.ncbi.nlm.nih.gov\/34812326\/<\/a>.<\/li>
  489. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https:\/\/pubmed.ncbi.nlm.nih.gov\/34006408\/<\/a><\/li>
  490. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https:\/\/pubmed.ncbi.nlm.nih.gov\/34416184\/<\/a><\/li>
  491. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: https:\/\/pubmed.ncbi.nlm.nih.gov\/34664303\/<\/a>.<\/li>
  492. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34649281\/<\/a>.<\/li>
  493. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34420249\/<\/a><\/li>
  494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34610990\/<\/a>.<\/li>
  495. Sweet\u2019s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: https:\/\/pubmed.ncbi.nlm.nih.gov\/34590397\/<\/a><\/li>
  496. Sudden sensorineural hearing loss after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34670143\/<\/a>.<\/li>
  497. Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/34819146\/<\/a>.<\/li>
  498. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34581453\/<\/a><\/li>
  499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34741583\/<\/a><\/li>
  500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34631069\/<\/a><\/li>
  501. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https:\/\/pubmed.ncbi.nlm.nih.gov\/34479129\/<\/a><\/li>
  502. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34331506\/<\/a><\/li>
  503. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): https:\/\/pubmed.ncbi.nlm.nih.gov\/34546608\/<\/a><\/li>
  504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34546343\/<\/a><\/li>
  505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34849183\/<\/a><\/li>
  506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34853744\/<\/a>.<\/li>
  507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): https:\/\/pubmed.ncbi.nlm.nih.gov\/34751429\/<\/a>.<\/li>
  508. Ocular adverse events following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34559576\/<\/a><\/li>
  509. Depression after ChAdOx1-S \/ nCoV-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34608345\/<\/a>.<\/li>
  510. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34384129\/<\/a>.<\/li>
  511. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https:\/\/pubmed.ncbi.nlm.nih.gov\/34755433\/<\/a><\/li>
  512. Major artery thrombosis and vaccination against ChAdOx1 nCov-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34839830\/<\/a><\/li>
  513. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: https:\/\/pubmed.ncbi.nlm.nih.gov\/34667486\/<\/a><\/li>
  514. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https:\/\/pubmed.ncbi.nlm.nih.gov\/34726187\/<\/a>.<\/li>
  515. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34781027\/<\/a><\/li>
  516. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34595694\/<\/a><\/li>
  517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: https:\/\/pubmed.ncbi.nlm.nih.gov\/34661934\/<\/a><\/li>
  518. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34788138<\/a><\/li>
  519. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34753210\/<\/a>.<\/li>
  520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34653943\/<\/a>.<\/li>
  521. Relapse of immune thrombocytopenia after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34591991\/<\/a><\/li>
  522. Thrombosis in pre- and post-vaccination phase of COVID-19; https:\/\/pubmed.ncbi.nlm.nih.gov\/34650382\/<\/a><\/li>
  523. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https:\/\/pubmed.ncbi.nlm.nih.gov\/34769454\/<\/a><\/li>
  524. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: https:\/\/pubmed.ncbi.nlm.nih.gov\/34786893\/<\/a><\/li>
  525. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34833382\/<\/a><\/li>
  526. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): https:\/\/pubmed.ncbi.nlm.nih.gov\/34670287\/<\/a><\/li>
  527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34790811\/<\/a><\/li>
  528. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https:\/\/pubmed.ncbi.nlm.nih.gov\/34023956\/<\/a>.<\/li>
  529. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: https:\/\/pubmed.ncbi.nlm.nih.gov\/34629931\/<\/a><\/li>
  530. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https:\/\/pubmed.ncbi.nlm.nih.gov\/34402666\/<\/a><\/li>
  531. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34842783\/<\/a><\/li>
  532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34630307\/<\/a><\/li>
  533. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33983464\/<\/a><\/li>
  534. Autoimmune roots of thrombotic events after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34508917\/<\/a>.<\/li>
  535. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: https:\/\/www.jcehepatology.com\/article\/S0973-6883(21)00545-4\/fulltext<\/a>.<\/li>
  536. Images of immune thrombotic thrombocytopenia induced by Oxford \/ AstraZeneca\u00ae COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33962903\/<\/a>.<\/li>
  537. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34796065\/<\/a>.<\/li>
  538. Increased risk of urticaria\/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https:\/\/pubmed.ncbi.nlm.nih.gov\/34579248\/<\/a><\/li>
  539. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34843991\/<\/a><\/li>
  540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): https:\/\/pubmed.ncbi.nlm.nih.gov\/34595867\/<\/a><\/li>
  541. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): https:\/\/pubmed.ncbi.nlm.nih.gov\/34820240\/<\/a><\/li>
  542. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton\u2019s tyrosine kinase inhibitors: https:\/\/pubmed.ncbi.nlm.nih.gov\/33851389\/<\/a><\/li>
  543. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: https:\/\/pubmed.ncbi.nlm.nih.gov\/33980419\/<\/a><\/li>
  544. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34264151\/<\/a><\/li>
  545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: https:\/\/pubmed.ncbi.nlm.nih.gov\/34734086\/<\/a><\/li>
  546. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: https:\/\/pubmed.ncbi.nlm.nih.gov\/34755555\/<\/a><\/li>
  547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/34407607\/<\/a><\/li>
  548. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34264514\/<\/a>.<\/li>
  549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): https:\/\/pubmed.ncbi.nlm.nih.gov\/34840204\/<\/a><\/li>
  550. Neurological side effects of SARS-CoV-2 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34750810\/<\/a><\/li>
  551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https:\/\/pubmed.ncbi.nlm.nih.gov\/34639132\/<\/a><\/li>
  552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: https:\/\/pubmed.ncbi.nlm.nih.gov\/34804412\/<\/a><\/li>
  553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34571653\/<\/a>.<\/li>
  554. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: https:\/\/pubmed.ncbi.nlm.nih.gov\/34835275\/<\/a>.<\/li>
  555. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: https:\/\/pubmed.ncbi.nlm.nih.gov\/34659839\/<\/a>.<\/li>
  556. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34668274\/<\/a>.<\/li>
  557. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34549821\/<\/a><\/li>
  558. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): https:\/\/pubmed.ncbi.nlm.nih.gov\/34528522\/<\/a><\/li>
  559. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34568726\/<\/a><\/li>
  560. Epidemiology of acute myocarditis\/pericarditis in Hong Kong adolescents after co-vaccination: https:\/\/academic.oup.com\/cid\/advance-article-abstract\/doi\/10.1093\/cid\/ciab989\/644 5179<\/a>.<\/li>
  561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciab926\/6420408<\/a><\/li>
  562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https:\/\/www.mdpi.com\/2075-4426\/11\/11\/1106<\/a><\/li>
  563. Epidemiology and clinical features of myocarditis\/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34402230\/<\/a><\/li>
  564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https:\/\/pubmed.ncbi.nlm.nih.gov\/34696294\/<\/a><\/li>
  565. Myocarditis Following mRNA COVID-19 Vaccine: https:\/\/journals.lww.com\/pec-online\/Abstract\/2021\/11000\/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx<\/a>.<\/li>
  566. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: https:\/\/pubmed.ncbi.nlm.nih.gov\/34614328\/<\/a>.<\/li>
  567. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: https:\/\/www.heartlungcirc.org\/article\/S1443-9506(21)01156-2\/fulltext<\/a><\/li>
  568. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34277198\/<\/a><\/li>
  569. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: https:\/\/pubmed.ncbi.nlm.nih.gov\/34246586\/<\/a><\/li>
  570. Hypersensitivity Myocarditis and COVID-19 Vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34856634\/<\/a>.<\/li>
  571. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: https:\/\/www.internationaljournalofcardiology.com\/article\/S0167-5273(21)01477-7\/fulltext<\/a>.<\/li>
  572. Acute myocardial infarction and myocarditis after COVID-19 vaccination: https:\/\/www.ncbi.nlm.nih.gov\/labs\/pmc\/articles\/PMC8522388\/<\/a><\/li>
  573. Myocarditis after Covid-19 vaccination in a large healthcare organization: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2110737<\/a><\/li>
  574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2783052<\/a><\/li>
  575. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed<\/a><\/li>
  576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https:\/\/pubmed.ncbi.nlm.nih.gov\/34756746\/<\/a><\/li>
  577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: https:\/\/www.ncbi.nlm.nih.gov\/labs\/pmc\/articles\/PMC8587334\/<\/a><\/li>
  578. Myocarditis after COVID-19 mRNA vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34546329\/<\/a>.<\/li>
  579. Patients with acute myocarditis after COVID-19 mRNA vaccination:. https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2781602<\/a>.<\/li>
  580. Myocarditis after COVID-19 vaccination: a case series: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X21011725?via%3Dihub<\/a>.<\/li>
  581. Myocarditis associated with COVID-19 vaccination in adolescents: https:\/\/publications.aap.org\/pediatrics\/article\/148\/5\/e2021053427\/181357<\/a><\/li>
  582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. https:\/\/pubmed.ncbi.nlm.nih.gov\/34704459\/<\/a><\/li>
  583. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: https:\/\/academic.oup.com\/ehjcimaging\/advance-article\/doi\/10.1093\/ehjci\/jeab230\/6 421640<\/a>.<\/li>
  584. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: https:\/\/www.ncbi.nlm.nih.gov\/labs\/pmc\/articles\/PMC8599115\/<\/a><\/li>
  585. Myocarditis after COVID-19 vaccination: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352906721001603<\/a><\/li>
  586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34712717\/<\/a>.<\/li>
  587. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https:\/\/www.revespcardiol.org\/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X<\/a>.<\/li>
  588. Myocarditis associated with COVID-19 mRNA vaccination: https:\/\/pubs.rsna.org\/doi\/10.1148\/radiol.2021211430<\/a><\/li>
  589. Acute myocarditis after COVID-19 vaccination: a case report: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0248866321007098<\/a><\/li>
  590. Acute myopericarditis after COVID-19 vaccination in adolescents:. https:\/\/pubmed.ncbi.nlm.nih.gov\/34589238\/<\/a>.<\/li>
  591. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: https:\/\/academic.oup.com\/jpids\/article\/10\/10\/962\/6329543<\/a>.<\/li>
  592. Acute myocarditis associated with anti-COVID-19 vaccination: https:\/\/ecevr.org\/DOIx.php?id=10.7774\/cevr.2021.10.2.196<\/a>.<\/li>
  593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. https:\/\/pubmed.ncbi.nlm.nih.gov\/34428917\/<\/a>.<\/li>
  594. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. https:\/\/pubmed.ncbi.nlm.nih.gov\/34088762\/<\/a>.<\/li>
  595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. https:\/\/academic.oup.com\/ehjqcco\/advance-article\/doi\/10.1093\/ehjqcco\/qcab090\/64<\/a> 42104.<\/li>
  596. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: https:\/\/www.mdpi.com\/2036-7503\/13\/3\/61<\/a>.<\/li>
  597. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34402228\/<\/a><\/li>
  598. Myocarditis temporally associated with COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34133885\/<\/a><\/li>
  599. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: https:\/\/pubmed.ncbi.nlm.nih.gov\/34219532\/<\/a><\/li>
  600. Acute myocarditis associated with COVID-19 vaccination: report of a case: https:\/\/www.ncbi.nlm.nih.gov\/labs\/pmc\/articles\/PMC8639400\/<\/a><\/li>
  601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34840235\/<\/a>.<\/li>
  602. Myocarditis in the setting of a recent COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34712497\/<\/a>.<\/li>
  603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: https:\/\/www.clinicalimaging.org\/article\/S0899-7071(21)00265-5\/fulltext<\/a>.<\/li>
  604. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34568726\/<\/a><\/li>
  605. Epidemiology of acute myocarditis\/pericarditis in Hong Kong adolescents after co-vaccination: https:\/\/academic.oup.com\/cid\/advance-article-abstract\/doi\/10.1093\/cid\/ciab989\/6445179<\/a><\/li>
  606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciab926\/6420408<\/a>.<\/li>
  607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https:\/\/www.mdpi.com\/2075-4426\/11\/11\/1106<\/a><\/li>
  608. Epidemiology and clinical features of myocarditis\/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34402230\/<\/a><\/li>
  609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https:\/\/pubmed.ncbi.nlm.nih.gov\/34696294\/<\/a><\/li>
  610. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34615534\/<\/a><\/li>
  611. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34352418\/<\/a><\/li>
  612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; https:\/\/jnnp.bmj.com\/content\/early\/2021\/09\/29\/jnnp-2021-327340<\/a>.<\/li>
  613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: https:\/\/pubmed.ncbi.nlm.nih.gov\/34632750\/<\/a><\/li>
  614. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: https:\/\/haematologica.org\/article\/view\/haematol.2021.279075<\/a><\/li>
  615. COVID-19 vaccine-induced thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34802488\/<\/a>.<\/li>
  616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34887867\/<\/a>.<\/li>
  617. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34863404\/<\/a>.<\/li>
  618. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S235255682100093X<\/a><\/li>
  619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34876440\/<\/a><\/li>
  620. Deep venous thrombosis more than two weeks after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33928773\/<\/a><\/li>
  621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/34880826\/<\/a><\/li>
  622. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: https:\/\/pubmed.ncbi.nlm.nih.gov\/34587242\/<\/a><\/li>
  623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/34868465\/<\/a><\/li>
  624. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): https:\/\/pubmed.ncbi.nlm.nih.gov\/34097311\/<\/a><\/li>
  625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: https:\/\/pubmed.ncbi.nlm.nih.gov\/34820232\/<\/a>.<\/li>
  626. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26258<\/a><\/li>
  627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34579636\/<\/a><\/li>
  628. Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: https:\/\/pubmed.ncbi.nlm.nih.gov\/34614491\/<\/a><\/li>
  629. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: https:\/\/pubmed.ncbi.nlm.nih.gov\/34790684\/<\/a><\/li>
  630. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): https:\/\/pubmed.ncbi.nlm.nih.gov\/33624509\/<\/a>.<\/li>
  631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): https:\/\/pubmed.ncbi.nlm.nih.gov\/34612003\/<\/a><\/li>
  632. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: https:\/\/pubmed.ncbi.nlm.nih.gov\/34096082\/<\/a><\/li>
  633. Myocarditis associated with COVID-19 vaccination in three adolescent boys: https:\/\/pubmed.ncbi.nlm.nih.gov\/34851078\/<\/a>.<\/li>
  634. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34496880\/<\/a><\/li>
  635. Perimyocarditis after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34866957\/<\/a><\/li>
  636. Epidemiology of acute myocarditis\/pericarditis in Hong Kong adolescents after co-vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34849657\/<\/a>.<\/li>
  637. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: https:\/\/pubmed.ncbi.nlm.nih.gov\/34664804\/<\/a><\/li>
  638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https:\/\/pubmed.ncbi.nlm.nih.gov\/34605853\/<\/a><\/li>
  639. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: https:\/\/pubmed.ncbi.nlm.nih.gov\/34166671\/<\/a><\/li>
  640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34744118\/<\/a><\/li>
  641. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: https:\/\/pubmed.ncbi.nlm.nih.gov\/34334935\/<\/a>.<\/li>
  642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34746968\/<\/a><\/li>
  643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?\u201d: https:\/\/pubmed.ncbi.nlm.nih.gov\/34333695\/<\/a>.<\/li>
  644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34180390\/<\/a><\/li>
  645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: https:\/\/pubmed.ncbi.nlm.nih.gov\/34185045\/<\/a><\/li>
  646. Myocarditis after BNT162b2 vaccination in a healthy male: https:\/\/pubmed.ncbi.nlm.nih.gov\/34229940\/<\/a><\/li>
  647. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34133825\/<\/a><\/li>
  648. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34308326\/<\/a>.<\/li>
  649. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: https:\/\/pubmed.ncbi.nlm.nih.gov\/34866106\/<\/a><\/li>
  650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34487236\/<\/a><\/li>
  651. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: https:\/\/pubmed.ncbi.nlm.nih.gov\/34848416\/<\/a><\/li>
  652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: https:\/\/pubmed.ncbi.nlm.nih.gov\/34636504\/<\/a><\/li>
  653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: https:\/\/pubmed.ncbi.nlm.nih.gov\/34367386\/<\/a><\/li>
  654. Acute myocarditis in a young adult two days after vaccination with Pfizer: https:\/\/pubmed.ncbi.nlm.nih.gov\/34709227\/<\/a><\/li>
  655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https:\/\/pubmed.ncbi.nlm.nih.gov\/34778411\/<\/a><\/li>
  656. Acute myocarditis after 2019 coronavirus disease vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34734821\/<\/a><\/li>
  657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34246585\/<\/a><\/li>
  658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: https:\/\/pubmed.ncbi.nlm.nih.gov\/34228985\/<\/a><\/li>
  659. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: https:\/\/pubmed.ncbi.nlm.nih.gov\/34852213\/<\/a><\/li>
  660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: https:\/\/pubmed.ncbi.nlm.nih.gov\/34866122\/<\/a><\/li>
  661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34601566\/<\/a><\/li>
  662. Myocarditis following COVID-19 vaccination: MRI study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34739045\/<\/a>.<\/li>
  663. Acute myocarditis after COVID-19 vaccination: case report: https:\/\/docs.google.com\/document\/d\/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl\/e<\/a><\/li>
  664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: https:\/\/pubmed.ncbi.nlm.nih.gov\/34374740\/<\/a><\/li>
  665. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https:\/\/pubmed.ncbi.nlm.nih.gov\/34865500\/<\/a><\/li>
  666. Myocarditis following vaccination with Covid-19 in a large healthcare organization: https:\/\/pubmed.ncbi.nlm.nih.gov\/34614329\/<\/a><\/li>
  667. AstraZeneca COVID-19 vaccine and Guillain-Barr\u00e9 syndrome in Tasmania: a causal link: https:\/\/pubmed.ncbi.nlm.nih.gov\/34560365\/<\/a><\/li>
  668. COVID-19, Guillain-Barr\u00e9 and vaccineA dangerous mix: https:\/\/pubmed.ncbi.nlm.nih.gov\/34108736\/<\/a>.<\/li>
  669. Guillain-Barr\u00e9 syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34796417\/<\/a>.<\/li>
  670. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: https:\/\/link.springer.com\/article\/10.1007%2Fs10072-021-05523-5<\/a>.<\/li>
  671. COVID-19 adenovirus vaccines and Guillain-Barr\u00e9 syndrome with facial palsy: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.26258<\/a>.<\/li>
  672. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2785009<\/a><\/li>
  673. A case of Guillain-Barr\u00e9 syndrome after Pfizer COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34567447\/<\/a><\/li>
  674. Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34648420\/<\/a>.<\/li>
  675. Rate of recurrent Guillain-Barr\u00e9 syndrome after COVID-19 BNT162b2 mRNA vaccine: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2783708<\/a><\/li>
  676. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: https:\/\/www.pedneur.com\/article\/S0887-8994(21)00221-6\/fulltext<\/a>.<\/li>
  677. Guillain-Barre syndrome after ChAdOx1-S \/ nCoV-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34114256\/<\/a>.<\/li>
  678. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34767184\/<\/a>.<\/li>
  679. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: https:\/\/pubmed.ncbi.nlm.nih.gov\/34644738\/<\/a>.<\/li>
  680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: https:\/\/pubmed.ncbi.nlm.nih.gov\/34649856\/<\/a><\/li>
  681. A rare case of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34671572\/<\/a><\/li>
  682. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33758714\/<\/a><\/li>
  683. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: https:\/\/pubmed.ncbi.nlm.nih.gov\/34484780\/<\/a><\/li>
  684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; https:\/\/pubmed.ncbi.nlm.nih.gov\/34779385\/<\/a>.<\/li>
  685. Miller Fisher syndrome after Pfizer COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34817727\/<\/a>.<\/li>
  686. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34789193\/<\/a>.<\/li>
  687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34261746\/<\/a><\/li>
  688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34217513\/<\/a>.<\/li>
  689. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): https:\/\/pubmed.ncbi.nlm.nih.gov\/34871447\/<\/a><\/li>
  690. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: https:\/\/pubmed.ncbi.nlm.nih.gov\/34579259\/<\/a><\/li>
  691. A variant of Guillain-Barr\u00e9 syndrome after SARS-CoV-2 vaccination: AMSAN: https:\/\/pubmed.ncbi.nlm.nih.gov\/34370408\/<\/a>.<\/li>
  692. A rare variant of Guillain-Barr\u00e9 syndrome after vaccination with Ad26.COV2.S: https:\/\/pubmed.ncbi.nlm.nih.gov\/34703690\/<\/a>.<\/li>
  693. Guillain-Barr\u00e9 syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barr\u00e9 syndrome: https:\/\/pubmed.ncbi.nlm.nih.gov\/34810163\/<\/a><\/li>
  694. Guillain-Barr\u00e9 syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.26218<\/a>.<\/li>
  695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34482455\/<\/a>.<\/li>
  696. Variant Guillain-Barr\u00e9 syndrome occurring after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34114269\/<\/a>.<\/li>
  697. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34722067\/<\/a><\/li>
  698. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https:\/\/pubmed.ncbi.nlm.nih.gov\/33968610\/<\/a><\/li>
  699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barr\u00e9 syndrome but also by distal small fiber neuropathy: https:\/\/pubmed.ncbi.nlm.nih.gov\/34525410\/<\/a><\/li>
  700. Clinical variant of Guillain-Barr\u00e9 syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34808658\/<\/a><\/li>
  701. Adverse event reporting and risk of Bell\u2019s palsy after COVID-19 vaccination: https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(21)00646-0\/fulltext<\/a>.<\/li>
  702. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: https:\/\/pubmed.ncbi.nlm.nih.gov\/34522557\/<\/a><\/li>
  703. Left Bell\u2019s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34763263\/<\/a>.<\/li>
  704. Bell\u2019s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell\u2019s palsy: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34621891\/<\/a><\/li>
  705. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: https:\/\/pubmed.ncbi.nlm.nih.gov\/34697502\/<\/a><\/li>
  706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell\u2019s palsy: https:\/\/pubmed.ncbi.nlm.nih.gov\/33858693\/<\/a><\/li>
  707. Acute transverse myelitis following inactivated COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34370410\/<\/a><\/li>
  708. Acute transverse myelitis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34579245\/<\/a>.<\/li>
  709. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34182207\/<\/a><\/li>
  710. Post COVID-19 transverse myelitis; a case report with review of the literature: https:\/\/pubmed.ncbi.nlm.nih.gov\/34457267\/<\/a>.<\/li>
  711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34189662\/<\/a><\/li>
  712. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: https:\/\/pubmed.ncbi.nlm.nih.gov\/34660149\/<\/a><\/li>
  713. Acute bilateral bilateral optic neuritis\/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34131771\/<\/a><\/li>
  714. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: https:\/\/pubmed.ncbi.nlm.nih.gov\/34635376\/<\/a><\/li>
  715. Acute pericarditis and cardiac tamponade after vaccination with Covid-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34749492\/<\/a><\/li>
  716. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34849667\/<\/a><\/li>
  717. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34319393\/<\/a><\/li>
  718. Acute myopericarditis after COVID-19 vaccine in adolescents: https:\/\/pubmed.ncbi.nlm.nih.gov\/34589238\/<\/a><\/li>
  719. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34149145\/<\/a><\/li>
  720. Case report: symptomatic pericarditis post COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34693198\/<\/a>.<\/li>
  721. An outbreak of Still\u2019s disease after COVID-19 vaccination in a 34-year-old patient: https:\/\/pubmed.ncbi.nlm.nih.gov\/34797392\/<\/a><\/li>
  722. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): https:\/\/pubmed.ncbi.nlm.nih.gov\/34862234\/<\/a><\/li>
  723. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: https:\/\/pubmed.ncbi.nlm.nih.gov\/34396358\/<\/a>.<\/li>
  724. Miller-Fisher syndrome and Guillain-Barr\u00e9 syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34848426\/<\/a>.<\/li>
  725. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA\/DNA vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/33946748\/<\/a><\/li>
  726. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https:\/\/pubmed.ncbi.nlm.nih.gov\/34591186\/<\/a><\/li>
  727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34352309\/<\/a><\/li>
  728. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: https:\/\/pubmed.ncbi.nlm.nih.gov\/34804803\/<\/a>.<\/li>
  729. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34077572\/<\/a><\/li>
  730. Retinal hemorrhage after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34884407\/<\/a>.<\/li>
  731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34859017\/<\/a><\/li>
  732. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34783899\/<\/a><\/li>
  733. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34549178\/<\/a>.<\/li>
  734. Brain death in a vaccinated patient with COVID-19 infection: https:\/\/pubmed.ncbi.nlm.nih.gov\/34656887\/<\/a><\/li>
  735. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34236717\/<\/a>.<\/li>
  736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34729467\/<\/a>.<\/li>
  737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33932458\/<\/a><\/li>
  738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: https:\/\/pubmed.ncbi.nlm.nih.gov\/34092400\/742<\/a>.<\/li>
  739. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34754937\/<\/a><\/li>
  740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: https:\/\/pubmed.ncbi.nlm.nih.gov\/33771584\/<\/a><\/li>
  741. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34846583\/<\/a><\/li>
  742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34073536\/<\/a><\/li>
  743. Bell\u2019s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34411532\/<\/a><\/li>
  744. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.02.21267156v1<\/a><\/li>
  745. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: https:\/\/pubmed.ncbi.nlm.nih.gov\/33851711\/<\/a><\/li>
  746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34675550\/<\/a>.<\/li>
  747. Anaphylaxis after Modern COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34734159\/<\/a>.<\/li>
  748. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34698847\/<\/a><\/li>
  749. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34020815\/<\/a><\/li>
  750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine \u2013 United States, December 14 to 23, 2020: https:\/\/pubmed.ncbi.nlm.nih.gov\/33641264\/<\/a><\/li>
  751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine \u2013 United States, December 21, 2020 to January 10, 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/33641268\/<\/a><\/li>
  752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: https:\/\/pubmed.ncbi.nlm.nih.gov\/33834172\/<\/a><\/li>
  753. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34579211\/<\/a><\/li>
  754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: https:\/\/pubmed.ncbi.nlm.nih.gov\/34343674\/<\/a><\/li>
  755. Acute myocardial infarction and myocarditis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34586408\/<\/a><\/li>
  756. Takotsubo syndrome after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34539938\/<\/a>.<\/li>
  757. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34731486\/<\/a>.<\/li>
  758. Premature myocardial infarction or side effect of COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33824804\/<\/a><\/li>
  759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: https:\/\/pubmed.ncbi.nlm.nih.gov\/34807248\/<\/a><\/li>
  760. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34148772\/<\/a><\/li>
  761. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: https:\/\/pubmed.ncbi.nlm.nih.gov\/34702550\/<\/a><\/li>
  762. Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty\u00ae): https:\/\/pubmed.ncbi.nlm.nih.gov\/33895650\/<\/a><\/li>
  763. Deaths associated with recently launched SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34425384\/<\/a><\/li>
  764. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: https:\/\/pubmed.ncbi.nlm.nih.gov\/34703815\/<\/a><\/li>
  765. COVID-19 vaccine-induced urticarial vasculitis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34369046\/<\/a>.<\/li>
  766. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34280507\/<\/a>.<\/li>
  767. New-onset leukocytoclastic vasculitis after COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34241833\/<\/a><\/li>
  768. Cutaneous small vessel vasculitis after COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34529877\/<\/a>.<\/li>
  769. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33928638\/<\/a><\/li>
  770. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34836739\/<\/a><\/li>
  771. Vasculitis and bursitis in [ 18 F] FDG-PET\/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; https:\/\/pubmed.ncbi.nlm.nih.gov\/34495381\/<\/a>.<\/li>
  772. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34327795<\/a><\/li>
  773. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34660867\/<\/a>.<\/li>
  774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34659268\/<\/a><\/li>
  775. Reactivation of IgA vasculitis after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34848431\/<\/a><\/li>
  776. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34310759\/<\/a>.<\/li>
  777. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https:\/\/pubmed.ncbi.nlm.nih.gov\/34720009\/<\/a><\/li>
  778. A rare case of Henoch-Sch\u00f6nlein purpura after a case report of COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34518812\/<\/a><\/li>
  779. Cutaneous vasculitis following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34611627\/<\/a>.<\/li>
  780. Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: https:\/\/pubmed.ncbi.nlm.nih.gov\/34705320\/<\/a>.<\/li>
  781. IgA vasculitis following COVID-19 vaccination in an adult: https:\/\/pubmed.ncbi.nlm.nih.gov\/34779011\/<\/a><\/li>
  782. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34451967\/<\/a><\/li>
  783. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: https:\/\/pubmed.ncbi.nlm.nih.gov\/33928459\/<\/a><\/li>
  784. Reactivation of IgA vasculitis after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34250509\/<\/a><\/li>
  785. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34292611\/<\/a>.<\/li>
  786. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34530771\/<\/a>.<\/li>
  787. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https:\/\/pubmed.ncbi.nlm.nih.gov\/34245294\/<\/a>.<\/li>
  788. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https:\/\/pubmed.ncbi.nlm.nih.gov\/34599716\/<\/a>.<\/li>
  789. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: https:\/\/pubmed.ncbi.nlm.nih.gov\/34115904\/<\/a>.<\/li>
  790. Henoch-Sch\u00f6nlein purpura occurring after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34247902\/<\/a>.<\/li>
  791. Henoch-Sch\u00f6nlein purpura following the first dose of COVID-19 viral vector vaccine: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34696186\/<\/a>.<\/li>
  792. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34237323\/<\/a>.<\/li>
  793. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34851795\/<\/a>.<\/li>
  794. A case of generalized Sweet\u2019s syndrome with vasculitis triggered by recent vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34849386\/<\/a><\/li>
  795. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34310763\/<\/a><\/li>
  796. Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34251683\/<\/a>.<\/li>
  797. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34557622\/<\/a>.<\/li>
  798. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment \u2013 A report of 3 cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34510694\/<\/a><\/li>
  799. Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: https:\/\/pubmed.ncbi.nlm.nih.gov\/34713472\/803<\/a><\/li>
  800. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: https:\/\/pubmed.ncbi.nlm.nih.gov\/34819272\/<\/a><\/li>
  801. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https:\/\/pubmed.ncbi.nlm.nih.gov\/34337124\/<\/a><\/li>
  802. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: https:\/\/pubmed.ncbi.nlm.nih.gov\/34535924\/<\/a><\/li>
  803. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.798095\/<\/a><\/li>
  804. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET \/ CT: https:\/\/pubmed.ncbi.nlm.nih.gov\/33591026\/<\/a><\/li>
  805. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: https:\/\/pubmed.ncbi.nlm.nih.gov\/33625300\/<\/a><\/li>
  806. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https:\/\/pubmed.ncbi.nlm.nih.gov\/33774684\/<\/a><\/li>
  807. Lymphadenopathy after COVID-19 vaccination: review of imaging findings: https:\/\/pubmed.ncbi.nlm.nih.gov\/33985872\/<\/a><\/li>
  808. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET\/CT after 2-dose COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34735411\/<\/a><\/li>
  809. Lymphadenopathy associated with COVID-19 vaccination on FDG PET\/CT: distinguishing features in adenovirus-vectored vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34115709\/<\/a>.<\/li>
  810. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: https:\/\/pubmed.ncbi.nlm.nih.gov\/34257025\/<\/a>.<\/li>
  811. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: https:\/\/pubmed.ncbi.nlm.nih.gov\/34836672\/<\/a>.<\/li>
  812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: https:\/\/pubmed.ncbi.nlm.nih.gov\/34280870\/<\/a><\/li>
  813. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: https:\/\/pubmed.ncbi.nlm.nih.gov\/34432391\/<\/a><\/li>
  814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: https:\/\/pubmed.ncbi.nlm.nih.gov\/34731748\/<\/a><\/li>
  815. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: https:\/\/pubmed.ncbi.nlm.nih.gov\/34906409\/<\/a><\/li>
  816. Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/33706861\/<\/a><\/li>
  817. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https:\/\/pubmed.ncbi.nlm.nih.gov\/34116295\/<\/a><\/li>
  818. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET \/ CT, not just an FDG finding: https:\/\/pubmed.ncbi.nlm.nih.gov\/33661328\/<\/a><\/li>
  819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34050949\/<\/a><\/li>
  820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https:\/\/pubmed.ncbi.nlm.nih.gov\/33624520\/<\/a><\/li>
  821. A case of cervical lymphadenopathy following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34141500\/<\/a><\/li>
  822. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34096896\/<\/a><\/li>
  823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https:\/\/pubmed.ncbi.nlm.nih.gov\/34835256\/<\/a><\/li>
  824. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https:\/\/pubmed.ncbi.nlm.nih.gov\/33713605\/<\/a><\/li>
  825. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https:\/\/pubmed.ncbi.nlm.nih.gov\/34298342\/<\/a><\/li>
  826. A systematic review of cases of CNS demyelination following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34839149\/<\/a><\/li>
  827. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https:\/\/pubmed.ncbi.nlm.nih.gov\/33685772\/<\/a><\/li>
  828. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https:\/\/pubmed.ncbi.nlm.nih.gov\/34719892\/<\/a><\/li>
  829. Adenopathy after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33625299\/<\/a>.<\/li>
  830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34292295\/<\/a>.<\/li>
  831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https:\/\/pubmed.ncbi.nlm.nih.gov\/33947605\/<\/a>.<\/li>
  832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https:\/\/pubmed.ncbi.nlm.nih.gov\/34526175\/<\/a><\/li>
  833. Lymphadenopathy associated with the COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33786231\/<\/a><\/li>
  834. Evolution of lymphadenopathy on PET\/MRI after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33625301\/<\/a>.<\/li>
  835. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34332438\/<\/a>.<\/li>
  836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https:\/\/pubmed.ncbi.nlm.nih.gov\/34342187\/<\/a>.<\/li>
  837. Massive cervical lymphadenopathy following vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34601889\/<\/a><\/li>
  838. ANCA glomerulonephritis following Modern COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34081948\/<\/a><\/li>
  839. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34507942\/<\/a>.<\/li>
  840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https:\/\/pubmed.ncbi.nlm.nih.gov\/34362727\/<\/a><\/li>
  841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https:\/\/pubmed.ncbi.nlm.nih.gov\/34325221\/<\/a><\/li>
  842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https:\/\/pubmed.ncbi.nlm.nih.gov\/34825530\/<\/a>.<\/li>
  843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34000278\/<\/a><\/li>
  844. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34655312\/<\/a>.<\/li>
  845. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34187985\/<\/a>.<\/li>
  846. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https:\/\/pubmed.ncbi.nlm.nih.gov\/33706861\/<\/a><\/li>
  847. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https:\/\/pubmed.ncbi.nlm.nih.gov\/34116295\/<\/a><\/li>
  848. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET \/ CT, not just an FDG finding: https:\/\/pubmed.ncbi.nlm.nih.gov\/33661328\/<\/a><\/li>
  849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34050949\/<\/a><\/li>
  850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https:\/\/pubmed.ncbi.nlm.nih.gov\/33624520\/<\/a><\/li>
  851. A case of cervical lymphadenopathy following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34141500\/<\/a><\/li>
  852. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https:\/\/pubmed.ncbi.nlm.nih.gov\/34096896\/<\/a><\/li>
  853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https:\/\/pubmed.ncbi.nlm.nih.gov\/34835256\/<\/a><\/li>
  854. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https:\/\/pubmed.ncbi.nlm.nih.gov\/33713605\/<\/a><\/li>
  855. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https:\/\/pubmed.ncbi.nlm.nih.gov\/34298342\/<\/a><\/li>
  856. A systematic review of cases of CNS demyelination following COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34839149\/<\/a><\/li>
  857. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https:\/\/pubmed.ncbi.nlm.nih.gov\/33685772\/<\/a><\/li>
  858. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https:\/\/pubmed.ncbi.nlm.nih.gov\/34719892\/<\/a><\/li>
  859. Adenopathy after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33625299\/<\/a>.<\/li>
  860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34292295\/<\/a>.<\/li>
  861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https:\/\/pubmed.ncbi.nlm.nih.gov\/33947605\/<\/a>.<\/li>
  862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https:\/\/pubmed.ncbi.nlm.nih.gov\/34526175\/<\/a><\/li>
  863. Lymphadenopathy associated with the COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/33786231\/<\/a><\/li>
  864. Evolution of lymphadenopathy on PET\/MRI after COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/33625301\/<\/a>.<\/li>
  865. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34332438\/<\/a>.<\/li>
  866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https:\/\/pubmed.ncbi.nlm.nih.gov\/34342187\/<\/a>.<\/li>
  867. Massive cervical lymphadenopathy following vaccination with COVID-19: https:\/\/pubmed.ncbi.nlm.nih.gov\/34601889\/<\/a><\/li>
  868. ANCA glomerulonephritis following Modern COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34081948\/<\/a><\/li>
  869. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34507942\/<\/a>.<\/li>
  870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https:\/\/pubmed.ncbi.nlm.nih.gov\/34362727\/<\/a><\/li>
  871. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https:\/\/pubmed.ncbi.nlm.nih.gov\/34325221\/<\/a><\/li>
  872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https:\/\/pubmed.ncbi.nlm.nih.gov\/34825530\/<\/a>.<\/li>
  873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https:\/\/pubmed.ncbi.nlm.nih.gov\/34000278\/<\/a><\/li>
  874. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https:\/\/pubmed.ncbi.nlm.nih.gov\/34655312\/<\/a>.<\/li>
  875. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https:\/\/pubmed.ncbi.nlm.nih.gov\/34187985\/<\/a>.<\/li>
  876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016\/j.ijcard.2021.08.018. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34416319<\/a><\/li>
  877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016\/j.vaccine.2021.05.087. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34092429<\/a><\/li>
  878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016\/j.radcr.2021.05.033. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34025885<\/a><\/li>
  879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093\/qjmed\/hcab252. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34586408<\/a><\/li>
  880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016\/j.jemermed.2021.09.017. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34756746<\/a><\/li>
  881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056\/NEJMoa2110475. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34432976<\/a><\/li>
  882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330\/wjc.v13.i10.556. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34754400<\/a><\/li>
  883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161\/CIRCULATIONAHA.121.056135. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34281357<\/a><\/li>
  884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390\/vaccines9111353. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34835284<\/a><\/li>
  885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459\/JCM.0000000000001232. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34366403<\/a><\/li>
  886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390\/pediatric13030061. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34564344<\/a><\/li>
  887. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111\/apa.16141. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34617315<\/a><\/li>
  888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007\/s00392-021-01916-w. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34333695<\/a><\/li>
  889. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390\/medicina57111163. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34833382<\/a><\/li>
  890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214\/AJR.21.26853. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34704459<\/a><\/li>
  891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346\/jkms.2021.36.e286. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34664804<\/a><\/li>
  892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002\/cpt.2499. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34860360<\/a><\/li>
  893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis\/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093\/cid\/ciab989. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34849657<\/a><\/li>
  894. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016\/j.jpeds.2021.12.026. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34933012<\/a><\/li>
  895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016\/j.ijid.2021.09.026. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34547487<\/a><\/li>
  896. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016\/j.jpeds.2021.07.044. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34339728<\/a><\/li>
  897. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390\/children8070607. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34356586<\/a><\/li>
  898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177\/21501327211029230. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34219532<\/a><\/li>
  899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016\/j.jcmg.2021.06.003. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34246585<\/a><\/li>
  900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002\/art.41977. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34492161<\/a><\/li>
  901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136\/annrheumdis-2021-221607. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34844930<\/a><\/li>
  902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007\/s00392-021-01936-6. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34487236<\/a><\/li>
  903. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056\/NEJMoa2113017. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34551225<\/a><\/li>
  904. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714\/3689.36746. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34709227<\/a><\/li>
  905. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002\/rmv.2318. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34921468<\/a><\/li>
  906. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038\/s41467-021-27120-y. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34824230<\/a><\/li>
  907. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2\/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https:\/\/doi.org\/10.1007\/s00392-020-01704-y<\/a>. Clin Res Cardiol, 110(8), 1352. doi:10.1007\/s00392-021-01896-x. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34170372<\/a><\/li>
  908. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093\/ehjqcco\/qcab090. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34849667<\/a><\/li>
  909. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389\/fimmu.2021.728021. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34646267<\/a><\/li>
  910. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136\/annrheumdis-2021-220647. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34127481<\/a><\/li>
  911. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016\/j.pcl.2021.05.004. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34538306<\/a><\/li>
  912. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices \u2013 United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585\/mmwr.mm7027e2. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34237049<\/a><\/li>
  913. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390\/vaccines9010019. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33406694<\/a><\/li>
  914. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al\u2019Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759\/cureus.17890. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34660088<\/a><\/li>
  915. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136\/bmj.n3090. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34916217<\/a><\/li>
  916. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016\/j.jaip.2021.06.006. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34153517<\/a><\/li>
  917. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414\/smw.2021.w30087. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34668687<\/a><\/li>
  918. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186\/s12872-021-02183-3. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34348657<\/a><\/li>
  919. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years \u2013 United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585\/mmwr.mm7031e1. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34351881<\/a><\/li>
  920. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147\/JBM.S307047. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33854395<\/a><\/li>
  921. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136\/bmj.n1931. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34446426<\/a><\/li>
  922. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622\/smedj.2021210. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34808708<\/a><\/li>
  923. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007\/s40264-021-01104-9. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34347278<\/a><\/li>
  924. In brief: Myocarditis with the Pfizer\/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34544112https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3454412<\/a><\/li>
  925. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093\/qjmed\/hcab231. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34463755<\/a><\/li>
  926. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093\/qjmed\/hcab326. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34931681<\/a><\/li>
  927. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148\/radiol.2021211766. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34342500<\/a><\/li>
  928. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542\/gcsp.2021.18. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34805376<\/a><\/li>
  929. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390\/v13112177. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34834983<\/a><\/li>
  930. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542\/peds.2021-053427. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34389692<\/a><\/li>
  931. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093\/jpids\/piab061. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34270752<\/a><\/li>
  932. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253\/circj.CJ-21-0818. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34744118<\/a><\/li>
  933. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016\/j.ijcha.2021.100872. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34568540<\/a><\/li>
  934. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759\/cureus.16590. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34447639<\/a><\/li>
  935. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001\/jamacardio.2021.2828. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34185046<\/a><\/li>
  936. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346\/jkms.2021.36.e229. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34402228<\/a><\/li>
  937. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016\/j.ahjo.2021.100042. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34396358<\/a><\/li>
  938. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001\/jama.2021.15072. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34477808<\/a><\/li>
  939. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007\/s40629-021-00165-7. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33898162<\/a><\/li>
  940. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer\/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007\/s40629-020-00160-4. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33643776<\/a><\/li>
  941. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016\/j.jpeds.2021.12.025. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34952008<\/a><\/li>
  942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to \u201cWhy are we vaccinating children against COVID-19?\u201d [Toxicol. Rep. 8C (2021) 1665-1684 \/ 1193]. Toxicol Rep, 8, 1981. doi:10.1016\/j.toxrep.2021.10.003. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34642628<\/a><\/li>
  943. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016\/j.toxrep.2021.08.010. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34540594<\/a><\/li>
  944. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007\/s00508-021-01922-y. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34378087<\/a><\/li>
  945. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038\/s41591-021-01413-7. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34127854<\/a><\/li>
  946. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809\/hkmj215120. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34393110<\/a><\/li>
  947. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to \u201cLetter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination\u201d. QJM. doi:10.1093\/qjmed\/hcab232. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34463770<\/a><\/li>
  948. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002\/ajh.26132. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33606296<\/a><\/li>
  949. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination \u2013 A case series. Vaccine, 39(42), 6195-6200. doi:10.1016\/j.vaccine.2021.09.004. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34535317<\/a><\/li>
  950. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038\/s41591-021-01330-9. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33888900<\/a><\/li>
  951. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390\/jpm11111106. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34834458<\/a><\/li>
  952. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389\/fcvm.2021.758996. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34778411<\/a><\/li>
  953. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016\/j.jpeds.2021.07.057. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34332972<\/a><\/li>
  954. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016\/j.cjca.2021.08.001. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34375696<\/a><\/li>
  955. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093\/cid\/ciab954. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34791081<\/a><\/li>
  956. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155\/2021\/6901131. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34676123<\/a><\/li>
  957. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002\/pbc.29295. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34398511<\/a><\/li>
  958. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016\/j.puhe.2020.11.005. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33316478<\/a><\/li>
  959. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111\/acem.14322. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34133825<\/a><\/li>
  960. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056\/NEJMoa2109730. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34614328<\/a><\/li>
  961. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016\/j.jpeds.2021.06.035. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34166671<\/a><\/li>
  962. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038\/s41467-021-26672-3. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34737312<\/a><\/li>
  963. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128\/IAI.00715-20. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33526560<\/a><\/li>
  964. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186\/s12879-021-06949-0. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34930152<\/a><\/li>
  965. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001\/jamacardio.2021.2833. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34185045<\/a><\/li>
  966. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169\/internalmedicine.8731-21. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34840235<\/a><\/li>
  967. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016\/j.jccase.2021.11.006. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34876937<\/a><\/li>
  968. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016\/j.clim.2021.108765. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34089859<\/a><\/li>
  969. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097\/INF.0000000000003389. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34889875<\/a><\/li>
  970. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038\/s41586-021-03841-4. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34320609<\/a><\/li>
  971. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis\/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346\/jkms.2021.36.e232. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34402230<\/a><\/li>
  972. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017\/S1047951121002547. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34180390<\/a><\/li>
  973. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186\/s12968-021-00795-4. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34496880<\/a><\/li>
  974. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038\/s41591-021-01630-0. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34907393<\/a><\/li>
  975. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016\/j.radcr.2021.07.082. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34367386<\/a><\/li>
  976. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093\/cid\/ciab926. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34734240<\/a><\/li>
  977. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736\/S0031-0808.21.04435-9. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34738774<\/a><\/li>
  978. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002\/ajh.26385. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34695229<\/a><\/li>
  979. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016\/j.ejca.2021.06.002. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34233234<\/a><\/li>
  980. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148\/ryct.210252. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34934954<\/a><\/li>
  981. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016\/j.jpeds.2021.06.083. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34228985<\/a><\/li>
  982. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007\/s00414-021-02706-9. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34591186<\/a><\/li>
  983. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007\/s00392-021-01880-5. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34241676<\/a><\/li>
  984. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390\/jcm10245876. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34945172<\/a><\/li>
  985. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389\/fimmu.2021.714170. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34707602<\/a><\/li>
  986. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine \u2013 United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585\/mmwr.mm7018e2. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33956784<\/a><\/li>
  987. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759\/cureus.16383. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34408937<\/a><\/li>
  988. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093\/ehjci\/jeab230. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34739045<\/a><\/li>
  989. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001\/jamainternmed.2021.5511. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34605853<\/a><\/li>
  990. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101\/2021.07.23.21260998. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34341797<\/a><\/li>
  991. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038\/s41591-021-01578-1. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34764489<\/a><\/li>
  992. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097\/INF.0000000000003235. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34077949<\/a><\/li>
  993. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016\/j.healun.2021.11.001. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34911654<\/a><\/li>
  994. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148\/radiol.2021211430. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34282971<\/a><\/li>
  995. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016\/j.carrev.2021.08.012. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34420869<\/a><\/li>
  996. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093\/ehjcr\/ytab319. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34514306<\/a><\/li>
  997. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253\/circj.CJ-21-0935. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34955479<\/a><\/li>
  998. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine \u2013 United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585\/mmwr.mm7002e1. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33444297<\/a><\/li>
  999. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056\/NEJMoa2107058. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34192428<\/a><\/li>
  1000. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177\/11795468211056634. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34866957<\/a><\/li>
  1001. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161\/CIRCULATIONAHA.121.056583. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34865500<\/a><\/li>
  1002. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016\/j.cpcardiol.2021.100926. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34311983<\/a><\/li>
  1003. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016\/j.cjco.2021.12.002. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34904134<\/a><\/li>
  1004. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759\/cureus.15576. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34277198<\/a><\/li>
  1005. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097\/PEC.0000000000002557. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34731877<\/a><\/li>
  1006. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001\/jamanetworkopen.2021.25524. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34533570<\/a><\/li>
  1007. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016\/j.ajem.2021.06.051. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34229940<\/a><\/li>
  1008. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389\/fpubh.2021.695807. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34336774<\/a><\/li>
  1009. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016\/j.vaccine.2021.04.054. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34006408<\/a><\/li>
  1010. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056\/NEJMoa2110737. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34614329<\/a><\/li>
  1011. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136\/archdischild-2020-320338. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33262177<\/a><\/li><\/ol>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study:
    \nFatal cerebral hemorrhage after COVID-19 vaccine:
    \nMyocarditis after mRNA vaccination<\/p>\n","protected":false},"author":1,"featured_media":1213,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_theme","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-1212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19_vaccines"],"yoast_head":"\n1011 CASE STUDIES into the COVID VACCINES - as the world turns<\/title>\n<meta name=\"description\" content=\"Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: Fatal cerebral hemorrhage after COVID-19 vaccine: Myocarditis after mRNA vaccination\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"1011 CASE STUDIES into the COVID VACCINES\" \/>\n<meta property=\"og:description\" content=\"Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: Fatal cerebral hemorrhage after COVID-19 vaccine: Myocarditis after mRNA vaccination\" \/>\n<meta property=\"og:url\" content=\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\" \/>\n<meta property=\"og:site_name\" content=\"as the world turns\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-01T14:00:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-15T23:07:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"357\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"fluffybits\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Guy4Good_1776\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\"},\"author\":{\"name\":\"fluffybits\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#\/schema\/person\/aec81ea84c0ddd4bca1832b45e90b8ed\"},\"headline\":\"1011 CASE STUDIES into the COVID VACCINES\",\"datePublished\":\"2022-03-01T14:00:30+00:00\",\"dateModified\":\"2024-06-15T23:07:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\"},\"wordCount\":22256,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#organization\"},\"image\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png\",\"articleSection\":[\"COVID-19 \/ Vaccines\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\",\"url\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\",\"name\":\"1011 CASE STUDIES into the COVID VACCINES - as the world turns\",\"isPartOf\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png\",\"datePublished\":\"2022-03-01T14:00:30+00:00\",\"dateModified\":\"2024-06-15T23:07:47+00:00\",\"description\":\"Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: Fatal cerebral hemorrhage after COVID-19 vaccine: Myocarditis after mRNA vaccination\",\"breadcrumb\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage\",\"url\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png\",\"contentUrl\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png\",\"width\":680,\"height\":357},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/astheworldturns.org\/wdp\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"1011 CASE STUDIES into the COVID VACCINES\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#website\",\"url\":\"https:\/\/astheworldturns.org\/wdp\/\",\"name\":\"as the world turns\",\"description\":\"only the truth\",\"publisher\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/astheworldturns.org\/wdp\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#organization\",\"name\":\"astheWorldTurns\",\"url\":\"https:\/\/astheworldturns.org\/wdp\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/NewLogoSmallest-1-1-1.png\",\"contentUrl\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/NewLogoSmallest-1-1-1.png\",\"width\":200,\"height\":200,\"caption\":\"astheWorldTurns\"},\"image\":{\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#\/schema\/person\/aec81ea84c0ddd4bca1832b45e90b8ed\",\"name\":\"fluffybits\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/astheworldturns.org\/wdp\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/litespeed\/avatar\/19b97e0732b38dd7a4cbb8c435f9c6c1.jpg?ver=1775074523\",\"contentUrl\":\"https:\/\/astheworldturns.org\/wdp\/wp-content\/litespeed\/avatar\/19b97e0732b38dd7a4cbb8c435f9c6c1.jpg?ver=1775074523\",\"caption\":\"fluffybits\"},\"sameAs\":[\"https:\/\/astheworldturns.org\/wdp\",\"https:\/\/x.com\/Guy4Good_1776\",\"https:\/\/soundcloud.com\/my_digital_alchemy\"],\"url\":\"https:\/\/astheworldturns.org\/wdp\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"1011 CASE STUDIES into the COVID VACCINES - as the world turns","description":"Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: Fatal cerebral hemorrhage after COVID-19 vaccine: Myocarditis after mRNA vaccination","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/","og_locale":"en_GB","og_type":"article","og_title":"1011 CASE STUDIES into the COVID VACCINES","og_description":"Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: Fatal cerebral hemorrhage after COVID-19 vaccine: Myocarditis after mRNA vaccination","og_url":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/","og_site_name":"as the world turns","article_published_time":"2022-03-01T14:00:30+00:00","article_modified_time":"2024-06-15T23:07:47+00:00","og_image":[{"width":680,"height":357,"url":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png","type":"image\/png"}],"author":"fluffybits","twitter_card":"summary_large_image","twitter_creator":"@Guy4Good_1776","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#article","isPartOf":{"@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/"},"author":{"name":"fluffybits","@id":"https:\/\/astheworldturns.org\/wdp\/#\/schema\/person\/aec81ea84c0ddd4bca1832b45e90b8ed"},"headline":"1011 CASE STUDIES into the COVID VACCINES","datePublished":"2022-03-01T14:00:30+00:00","dateModified":"2024-06-15T23:07:47+00:00","mainEntityOfPage":{"@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/"},"wordCount":22256,"commentCount":0,"publisher":{"@id":"https:\/\/astheworldturns.org\/wdp\/#organization"},"image":{"@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png","articleSection":["COVID-19 \/ Vaccines"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/","url":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/","name":"1011 CASE STUDIES into the COVID VACCINES - as the world turns","isPartOf":{"@id":"https:\/\/astheworldturns.org\/wdp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png","datePublished":"2022-03-01T14:00:30+00:00","dateModified":"2024-06-15T23:07:47+00:00","description":"Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: Fatal cerebral hemorrhage after COVID-19 vaccine: Myocarditis after mRNA vaccination","breadcrumb":{"@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#primaryimage","url":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png","contentUrl":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/story-1.png","width":680,"height":357},{"@type":"BreadcrumbList","@id":"https:\/\/astheworldturns.org\/wdp\/2022\/03\/01\/1011-case-studies-into-covid-vaccines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/astheworldturns.org\/wdp\/"},{"@type":"ListItem","position":2,"name":"1011 CASE STUDIES into the COVID VACCINES"}]},{"@type":"WebSite","@id":"https:\/\/astheworldturns.org\/wdp\/#website","url":"https:\/\/astheworldturns.org\/wdp\/","name":"as the world turns","description":"only the truth","publisher":{"@id":"https:\/\/astheworldturns.org\/wdp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/astheworldturns.org\/wdp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/astheworldturns.org\/wdp\/#organization","name":"astheWorldTurns","url":"https:\/\/astheworldturns.org\/wdp\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/astheworldturns.org\/wdp\/#\/schema\/logo\/image\/","url":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/NewLogoSmallest-1-1-1.png","contentUrl":"https:\/\/astheworldturns.org\/wdp\/wp-content\/uploads\/2022\/03\/NewLogoSmallest-1-1-1.png","width":200,"height":200,"caption":"astheWorldTurns"},"image":{"@id":"https:\/\/astheworldturns.org\/wdp\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/astheworldturns.org\/wdp\/#\/schema\/person\/aec81ea84c0ddd4bca1832b45e90b8ed","name":"fluffybits","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/astheworldturns.org\/wdp\/#\/schema\/person\/image\/","url":"https:\/\/astheworldturns.org\/wdp\/wp-content\/litespeed\/avatar\/19b97e0732b38dd7a4cbb8c435f9c6c1.jpg?ver=1775074523","contentUrl":"https:\/\/astheworldturns.org\/wdp\/wp-content\/litespeed\/avatar\/19b97e0732b38dd7a4cbb8c435f9c6c1.jpg?ver=1775074523","caption":"fluffybits"},"sameAs":["https:\/\/astheworldturns.org\/wdp","https:\/\/x.com\/Guy4Good_1776","https:\/\/soundcloud.com\/my_digital_alchemy"],"url":"https:\/\/astheworldturns.org\/wdp\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/posts\/1212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/comments?post=1212"}],"version-history":[{"count":0,"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/posts\/1212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/media\/1213"}],"wp:attachment":[{"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/media?parent=1212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/categories?post=1212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astheworldturns.org\/wdp\/wp-json\/wp\/v2\/tags?post=1212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}